Valuation: Vectus Biosystems Limited

Market Cap 7.69M 5.47M 4.69M 4.38M 4.02M 7.56M 523M 51.72M 20.25M 262M 20.55M 20.1M 867M P/E 2024
-1.75x
P/E 2025 -1.2x
Enterprise Value 7.64M 5.44M 4.66M 4.35M 3.99M 7.51M 520M 51.38M 20.12M 261M 20.41M 19.97M 862M EV / Sales 2024
2.91x
EV / Sales 2025 4.35x
Free-Float
57.14%
Yield 2024 *
-
Yield 2025 -
1 week+6.25%
Current month+30.77%
1 month-2.86%
3 months+73.47%
6 months+21.43%
Current year-5.56%
1 week 0.16
Extreme 0.16
0.17
1 month 0.13
Extreme 0.13
0.18
Current year 0.09
Extreme 0.09
0.22
1 year 0.05
Extreme 0.053
0.46
3 years 0.04
Extreme 0.037
0.46
5 years 0.04
Extreme 0.037
2.2
10 years 0.04
Extreme 0.037
2.2
Manager TitleAgeSince
Chief Executive Officer - 2026-05-06
Corporate Secretary - 2015-07-08
Director TitleAgeSince
Director/Board Member - 2005-12-11
Chairman - 2018-08-30
Director/Board Member - 2024-12-19
Change 5-day change 1-year change 3-year change Capi.($)
0.00%+6.25%+112.50%-57.50% 7.44M
+0.60%+1.85%+1.96%+24.15% 50.5B
-0.62%+4.58%+487.47%+624.71% 46.01B
+2.09%+4.96%+20.59%+95.21% 42.85B
+3.85%+3.13%+29.60%+16.50% 41.03B
-0.72%-3.91%+17.87%+47.98% 32.02B
+3.04%+1.89%+31.62%+143.62% 16.98B
+4.33%+1.63% - - 17.05B
+2.12%+2.94%+4.85%+34.23% 14.3B
+3.87%+1.98%+82.99%+45.80% 13.84B
Average +1.86%+1.81%+87.72%+108.30% 27.46B
Weighted average by Cap. +1.60%+2.37%+104.65%+154.60%

Financials

2024 2025
Net sales 1.14M 811K 695K 649K 596K 1.12M 77.48M 7.66M 3M 38.86M 3.04M 2.98M 128M 478K 340K 292K 273K 250K 470K 32.54M 3.22M 1.26M 16.32M 1.28M 1.25M 53.95M
Net income -2.34M -1.66M -1.43M -1.33M -1.22M -2.3M -159M -15.73M -6.16M -79.79M -6.25M -6.11M -264M -1.78M -1.27M -1.09M -1.01M -930K -1.75M -121M -11.96M -4.68M -60.65M -4.75M -4.65M -201M
Net Debt -780K -555K -476K -445K -408K -767K -53.08M -5.25M -2.06M -26.62M -2.09M -2.04M -88.01M -50.99K -36.3K -31.14K -29.07K -26.68K -50.16K -3.47M -343K -134K -1.74M -136K -133K -5.75M
Logo Vectus Biosystems Limited
Vectus Biosystems Limited is an Australia-based drug discovery and development company. The Company focuses on medical research and development. It is engaged in developing a treatment for fibrosis and high blood pressure, which includes the treatment for diseases in the fibrotic market, namely heart, kidney, and liver diseases. Its compound, VB0004, focuses on treating the hardening of functional tissue and high blood pressure. It also focuses on developing candidates for the treatment of fibrotic liver diseases, including non-alcoholic steatohepatitis (NASH) as well as pulmonary fibrotic diseases. The Company has also developed technology focused at improving the speed and accuracy of measuring the amount of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA) in samples tested in laboratories. Accugen is a platform, developed by its wholly owned subsidiary, Accugen Pty Limited, comprising of reagents, and software that quantitate polymerase chain reaction (qPCR) reactions.
Employees
-
Date Price Change Volume
26-08-19 A$0.1700 0.00% 35
26-08-19 A$0.1700 0.00% 11,764
26-08-18 A$0.1700 0.00% 30,018
26-08-17 A$0.1700 +6.25% 31,968